Company Data
Ikena Oncology Inc.
Ticker
IKNA
Current Price
$1.39 -4.14%
Market Cap
$67.1M
Price Target
Refer to Report
Volume
82.5K
52wk Range
$1.22 - $1.94
Overview
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.